A phase I safety, dose finding and feasibility trial of GD2-IL18 CART in patients with relapsed or refractory GD2 positive solid cancers

Studienkoordinator:
Univ.-Prof. Dr. Claudia Rössig, Münster

Beteiligte Wissenschaftler am IBKF:
Dr. rer. nat. Dennis Görlich